← Back to Search

LDCT Lung Screening for Early Detection of Lung Cancer

N/A

Recruiting

Led By Daniel Carrizosa, MD

Research Sponsored by Daniel Carrizosa

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 40-54 years at the time of consent.

Ability to read and understand the English and/or Spanish language.

Must not have

Known diagnosis of lung cancer in the past 5 years.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 24 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether lowering the minimum age for low-dose CT screening from 55 to 50 will decrease mortality in a high-risk population.

Who is the study for?

This trial is for people aged 40-54 who have a significant smoking history (at least 30 pack years), are currently smoking or quit within the last 15 years, and can understand English/Spanish. They must consent to share health information and follow study procedures. Those with past lung cancer diagnosis, CT scan contraindications, or pregnancy cannot join.

What is being tested?

The study tests if lowering the age for Low-dose Computed Tomography (LDCT) screening can help detect lung cancer earlier in smokers or recent quitters aged 40-54. This follows evidence that LDCT improves survival rates in older individuals.

What are the potential side effects?

While LDCT itself has minimal side effects, potential risks include exposure to low levels of radiation which may slightly increase the risk of developing cancer over one's lifetime.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 40 and 54 years old.

Select...

I can read and understand either English or Spanish.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I was diagnosed with lung cancer within the last 5 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Lung cancer diagnosis rate in individuals 40-54 years of age at their first screening (T0) with mobile low-dose CT.

Secondary study objectives

Impact of baseline demographic (including insurance status), socioeconomic, and healthcare-related factors on lung cancer rates and positive screening rates

Incidence rate of all types of cancer found with low-dose lung CT during lung cancer screening

Lung cancer diagnosis rate in individuals 40-54 years of age at subsequent screening visits (T1 and T2)

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Single ArmExperimental Treatment1 Intervention

Mobile Low-dose Computed Tomography (LDCT) Screening

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Daniel CarrizosaLead Sponsor

Leon Levine FoundationUNKNOWN

Wake Forest University Health SciencesLead Sponsor

1,403 Previous Clinical Trials

2,477,175 Total Patients Enrolled

Daniel Carrizosa, MD4.47 ReviewsPrincipal Investigator - LCI

Atrium Health

1 Previous Clinical Trials

329 Total Patients Enrolled

5Patient Review

I have been fortunate enough to know Dr. Carrizosa for a long time. His compassion, care and skill are unrivalled. He genuinely loves medicine and his patients, and this shines through at some of the most difficult times in people's lives.